Stay Connected. Stay Informed.
On the SSA, the company said it recorded ₹453 crore as a reduction of revenue from sale of goods in its Global Generics Segment. | Photo Credit: The Hindu Pharma major Dr. Reddy’s Laboratories reported consolidated net profit slumped to ₹221.3 crore for the March quarter compared to ₹1,586.7 crore a year earlier on the…
Read More “Dr. Reddy’s Q4 dips 86% on lower sales, multiple one offs to ₹221 crore” »
Dr. Reddy’s Laboratories on Friday (September 6, 2024) said it has received the establishment inspection report (EIR) from the U.S. health regulator for its active pharmaceutical ingredient manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh. The U.S. Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection…
Read More “Dr. Reddy’s gets inspection report from USFDA for Srikakulam-based API plant” »
Dr. Reddy’s had previously received EU (Good manufacturing practice) GMP certificate for its Rituximab drug substance and drug product manufacturing facility located in Hyderabad. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending launch of Dr. Reddy’s Laboratories’ proposed biosimilar Rituximab candidate DRL_RI…
Read More “Dr. Reddy’s biosimilar of Roche’s cancer drug gets EMA panel nod” »